Numerous studies suggested the clinical significance of Th-17 responses in contributing to poor survival outcome in HCC patients by the pro-tumor functions of IL-17, IL-21 and IL-22, including tumor proliferation and angiogenesis [26,27,28,29,30]. This evidence concerns the gene IL17A and hepatocellular carcinoma.